{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.7","value":"76.4"},{"groupId":"OG001","spread":"41.4","value":"80.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"Cycle 1 Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.7","value":"119"},{"groupId":"OG001","spread":"57.1","value":"130"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"322"},{"groupId":"OG001","value":"319"}],"units":"Participants"}],"title":"Cycle 2 Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.9","value":"146"},{"groupId":"OG001","spread":"102","value":"160"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"307"}],"units":"Participants"}],"title":"Cycle 3 Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"89.6","value":"219"},{"groupId":"OG001","spread":"99.0","value":"220"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"249"}],"units":"Participants"}],"title":"Cycle 7 Day 21"}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG001","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.","reportingStatus":"POSTED","timeFrame":"Day 21 of Cycles 1, 2 3, and 7 (Cycle length=21 days)","title":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Arm A and Arm B","type":"SECONDARY","unitOfMeasure":"mcg/mL"}